Patents by Inventor Nikhil V. Dhurandhar
Nikhil V. Dhurandhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220288159Abstract: Embodiments of the present disclosure pertain to methods of treating or preventing Alzheimer's disease or symptoms of Alzheimer's disease in a subject by administering to the subject an active agent that includes an adenovirus-36 E4orf1 protein, a nucleic acid encoding an adenovirus-36 E4orfl protein, or combinations thereof. Additional embodiments of the present disclosure pertain to the active agents of the present disclosure for use in the treatment or prevention of Alzheimer's disease or symptoms of Alzheimer's disease.Type: ApplicationFiled: August 7, 2020Publication date: September 15, 2022Applicant: Texas Tech University SystemInventors: Nikhil V. Dhurandhar, Vijay Hegde
-
Publication number: 20220071953Abstract: In an embodiment, the present disclosure pertains to compositions and methods for modulating cellular glucose uptake. In general, the methods include associating cells with the compositions of the present disclosure. In another aspect, the present disclosure pertains to compositions and methods to treat or prevent a disorder in a subject. The methods generally include administering the compositions of the present disclosure to the subject.Type: ApplicationFiled: January 8, 2020Publication date: March 10, 2022Applicant: Texas Tech University SystemInventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Patent number: 10047107Abstract: The invention relates to amino nitrile compounds. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: GrantFiled: April 21, 2015Date of Patent: August 14, 2018Assignee: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeInventors: Bhaskar C. Das, Nikhil V. Dhurandhar
-
Publication number: 20170340699Abstract: This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.Type: ApplicationFiled: January 6, 2015Publication date: November 30, 2017Inventor: NIKHIL V. DHURANDHAR
-
Patent number: 9714259Abstract: A compound includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: GrantFiled: May 23, 2016Date of Patent: July 25, 2017Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Publication number: 20170044189Abstract: A compound includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: ApplicationFiled: May 23, 2016Publication date: February 16, 2017Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Publication number: 20170037064Abstract: The invention relates to amino nitrile compounds. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: ApplicationFiled: April 21, 2015Publication date: February 9, 2017Inventors: Bhaskar C. DAS, Nikhil V. DHURANDHAR
-
Patent number: 9469659Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: GrantFiled: January 7, 2016Date of Patent: October 18, 2016Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Patent number: 9346835Abstract: A compound includes the structure of general Formula (II), pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: GrantFiled: October 16, 2013Date of Patent: May 24, 2016Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Publication number: 20160113951Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: ApplicationFiled: January 7, 2016Publication date: April 28, 2016Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Publication number: 20150266903Abstract: A compound includes the structure of general Formula (II), pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: ApplicationFiled: October 16, 2013Publication date: September 24, 2015Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Patent number: 8951980Abstract: This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.Type: GrantFiled: July 8, 2011Date of Patent: February 10, 2015Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Nikhil V. Dhurandhar
-
Publication number: 20150038412Abstract: This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor.Type: ApplicationFiled: January 18, 2013Publication date: February 5, 2015Inventors: Nikhil V. Dhurandhar, Rashmi Krishnapuram
-
Publication number: 20120027845Abstract: This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.Type: ApplicationFiled: July 8, 2011Publication date: February 2, 2012Applicant: Board of Supervisors of Louisiana State Universtiy & Agricultural and Mechanical CollegeInventor: Nikhil V. Dhurandhar
-
Publication number: 20120028893Abstract: Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.Type: ApplicationFiled: July 7, 2011Publication date: February 2, 2012Applicants: Wayne State University, Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventors: Nikhil V. Dhurandhar, Thomas C. Holland, Zhong Q. Wang
-
Patent number: 8008436Abstract: Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.Type: GrantFiled: November 30, 2006Date of Patent: August 30, 2011Assignees: Wayne State Univeristy, Board of Sup. of LSU and Agr. & Mechanical CollegeInventors: Nikhil V. Dhurandhar, Thomas C. Holland, Zhong Q. Wang
-
Publication number: 20090264356Abstract: Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.Type: ApplicationFiled: November 30, 2006Publication date: October 22, 2009Inventors: Nikhil V. Dhurandhar, Thomas C. Holland, Zhong Q. Wang
-
Publication number: 20090220946Abstract: Infection with obesifying adenoviruses in animals and humans may be used to predict changes in body weight and disease status. More particularly, infection with certain adenoviruses, such as adenovirus type 36 (Ad-36) and adenovirus type 37 (Ad-37) may cause removal of the normal equilibrium factors that control fat cell metabolism and may make individuals more responsive than normal individuals to perturbations, which cause body composition change including weight gain or weight loss.Type: ApplicationFiled: March 18, 2009Publication date: September 3, 2009Applicant: OBETECH, LLCInventors: Richard L. ATKINSON, Nikhil V. Dhurandhar
-
Patent number: RE40832Abstract: A source of viral induced obesity has been discovered. A virus known as AD-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.Type: GrantFiled: October 5, 2007Date of Patent: July 7, 2009Assignee: Obetech, LLCInventors: Richard L. Atkinson, Nikhil V. Dhurandhar
-
Patent number: RE42129Abstract: A source of viral induced obesity has been discovered. A virus known as AD-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.Type: GrantFiled: June 30, 2009Date of Patent: February 8, 2011Assignee: Obetech, LLCInventors: Richard L. Atkinson, Nikhil V. Dhurandhar